Group One Trading’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $136K | Sell |
97,687
-35,352
| -27% | -$48.6K | ﹤0.01% | 4442 |
|
|
2025
Q4 | $214K | Buy |
+133,039
| New | +$279K | ﹤0.01% | 4309 |
|
|
2024
Q4 | – | Sell |
-12,306
| Closed | -$21.4K | – | 7199 |
|
|
2024
Q3 | $16.2K | Buy |
+12,306
| New | +$16.4K | ﹤0.01% | 5347 |
|
|
2024
Q2 | – | Sell |
-20,678
| Closed | -$25.6K | – | 6642 |
|
|
2024
Q1 | $37.8K | Sell |
20,678
-29,029
| -58% | -$46.4K | ﹤0.01% | 4943 |
|
|
2023
Q4 | $61.6K | Sell |
49,707
-38,694
| -44% | -$39.5K | ﹤0.01% | 4899 |
|
|
2023
Q3 | $101K | Sell |
88,401
-78,801
| -47% | -$101K | ﹤0.01% | 4453 |
|
|
2023
Q2 | $153K | Sell |
167,202
-98,065
| -37% | -$94.7K | ﹤0.01% | 4210 |
|
|
2023
Q1 | $149K | Sell |
265,267
-106,771
| -29% | -$81.6K | ﹤0.01% | 3936 |
|
|
2022
Q4 | $215K | Sell |
372,038
-40,675
| -10% | -$12.7K | ﹤0.01% | 3801 |
|
|
2022
Q3 | $131K | Sell |
412,713
-55,251
| -12% | -$21.7K | ﹤0.01% | 4522 |
|
|
2022
Q2 | $165K | Buy |
467,964
+65,780
| +16% | +$27.6K | ﹤0.01% | 4483 |
|
|
2022
Q1 | $289K | Buy |
402,184
+336,783
| +515% | +$721K | ﹤0.01% | 4407 |
|
|
2021
Q4 | $148K | Buy |
65,401
+44,568
| +214% | +$122K | ﹤0.01% | 5382 |
|
|
2021
Q3 | $60K | Buy |
20,833
+3,469
| +20% | +$9.9K | ﹤0.01% | 6382 |
|
|
2021
Q2 | $66K | Sell |
17,364
-36,028
| -67% | -$121K | ﹤0.01% | 6331 |
|
|
2021
Q1 | $181K | Sell |
53,392
-41,272
| -44% | -$149K | ﹤0.01% | 5118 |
|
|
2020
Q4 | $265K | Buy |
94,664
+60,084
| +174% | +$175K | ﹤0.01% | 3848 |
|
|
2020
Q3 | $87K | Buy |
+34,580
| New | +$303K | ﹤0.01% | 4281 |
|
|
2020
Q2 | – | Sell |
-83,972
| Closed | -$869K | – | 5739 |
|
|
2020
Q1 | $637K | Buy |
83,972
+19,930
| +31% | +$155K | 0.01% | 1872 |
|
|
2019
Q4 | $405K | Sell |
64,042
-4,010
| -6% | -$19.1K | ﹤0.01% | 2611 |
|
|
2019
Q3 | $267K | Sell |
68,052
-2,025
| -3% | -$8.68K | ﹤0.01% | 2868 |
|
|
2019
Q2 | $339K | Buy |
+70,077
| New | +$399K | ﹤0.01% | 2487 |
|
|
2019
Q1 | – | Sell |
-8,142
| Closed | -$55.9K | – | 4739 |
|
|
2018
Q4 | $45K | Sell |
8,142
-4,906
| -38% | -$38.4K | ﹤0.01% | 3613 |
|
|
2018
Q3 | $115K | Buy |
13,048
+1,300
| +11% | +$11.6K | ﹤0.01% | 3428 |
|
|
2018
Q2 | $117K | Buy |
+11,748
| New | +$118K | ﹤0.01% | 3442 |
|
|
2017
Q4 | – | Sell |
-5,713
| Closed | -$94.7K | – | 4794 |
|
|
2017
Q3 | $112K | Buy |
+5,713
| New | +$87.8K | ﹤0.01% | 3160 |
|
|
2017
Q2 | – | Sell |
-25,662
| Closed | -$325K | – | 4701 |
|
|
2017
Q1 | $236K | Buy |
25,662
+14,211
| +124% | +$139K | ﹤0.01% | 2407 |
|
|
2016
Q4 | $119K | Sell |
11,451
-18,440
| -62% | -$159K | ﹤0.01% | 2740 |
|
|
2016
Q3 | $271K | Buy |
29,891
+5,389
| +22% | +$45.8K | ﹤0.01% | 2263 |
|
|
2016
Q2 | $183K | Buy |
24,502
+7,226
| +42% | +$63.1K | ﹤0.01% | 2463 |
|
|
2016
Q1 | $156K | Buy |
17,276
+10,040
| +139% | +$81.4K | ﹤0.01% | 2503 |
|
|
2015
Q4 | $93K | Sell |
7,236
-5,828
| -45% | -$59.5K | ﹤0.01% | 3013 |
|
|
2015
Q3 | $126K | Buy |
13,064
+4,311
| +49% | +$39.6K | ﹤0.01% | 2874 |
|
|
2015
Q2 | $90K | Sell |
8,753
-4,022
| -31% | -$34.3K | ﹤0.01% | 3158 |
|
|
2015
Q1 | $142K | Buy |
12,775
+1,397
| +12% | +$14.9K | ﹤0.01% | 2642 |
|
|
2014
Q4 | $132K | Buy |
11,378
+11,142
| +4,721% | +$160K | ﹤0.01% | 2629 |
|
|
2014
Q3 | $5K | Buy |
+236
| New | +$5.42K | ﹤0.01% | 4707 |
|
Other funds holding AKBA
VCM
VPM
Group One Trading's AKBA Position: Q1 2026 in Review
Group One Trading reduced its Akebia Therapeutics (AKBA) stake by 27% in Q1 2026, selling an estimated $48.6K and leaving 97,687 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #4442.
Group One Trading first reported a position in AKBA in Q3 2014 and has held it in 37 quarters since. The position peaked at $637K in Q1 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Group One Trading held 97,687 shares of Akebia Therapeutics worth $136K as of Q1 2026.
- Group One Trading sold 35,352 Akebia Therapeutics shares in Q1 2026, an estimated $48.6K.
- Akebia Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #4442 holding.
- Group One Trading first reported a position in Akebia Therapeutics in Q3 2014 and has held it in 37 quarters since.
- Group One Trading's Akebia Therapeutics position peaked at $637K in Q1 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.